‘’A Phase 2 clinical trial of simufilam, an experimental medication for Alzheimer’s disease, showed cognitive benefits in nearly half of the patients after one year of treatment. The medication was particularly effective for those in the early stages of the disease. Simufilam also demonstrated positive effects on depression and dementia-related behaviors. Phase 3 trials are currently enrolling participants to further investigate the safety and efficacy of simufilam. The goal is to develop an effective treatment for Alzheimer’s, a progressive disease characterized by memory loss, confusion, and cognitive decline.’’ 

To read the full article, click here: Simufilam aids cognition in 47% of Alzheimer’s patients in Phase 2 study | Top-line findings at one year in mild-to-moderate disease | Alzheimer’s News Today (alzheimersnewstoday.com)